Home
News
Create
Screeners
Insights
Lactose
114.
90
+6.60
(+6.09%)
Market Cap
₹144.61 Cr
PE Ratio
22.47
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+6.09%
1M
+1.62%
6M
-1.46%
1Y
+18.55%
5Y
+287.52%
View Company Insights
Latest news about Lactose
Lactose India FY26 Net Profit Rises 17% to ₹606.28 Lakh
May 20, 2026
Lactose (India) Limited reported a 17.4% increase in net profit to ₹606.28 lakh for FY26, driven by a 40.3% rise in revenue to ₹16,329.01 lakh. The company's Q4 net profit surged to ₹187.69 lakh, while its merger with Vitanosh Ingredients awaits regulatory approvals.
Lactose (India) Limited Submits Q4 FY26 Securities Dematerialization Certificate to BSE
Apr 14, 2026
Lactose India EGM Approves Vitanosh Merger with Overwhelming Shareholder Support
Mar 31, 2026
Lactose India Adopts New Business Line in Specialized Pharmaceutical Excipients with ₹15 Crore Investment
Jan 30, 2026
SST Private Family Trust Completes SEBI Disclosure for Lactose India Stake Transfer
Jan 16, 2026
More news about Lactose
24
Oct 25
Lactose India Limited's Credit Rating Reaffirmed at CRISIL BBB-/Stable
CRISIL Ratings Limited has reaffirmed the BBB-/Stable credit rating for Lactose India Limited's long-term bank facilities totaling Rs. 60.00 crore from Bank of Baroda. The rating covers cash credit, proposed working capital facilities, and term loans. The rating indicates moderate safety for timely servicing of financial obligations with moderate credit risk. The rating is valid until March 31, 2026.
23
Aug 25
Lactose (India) Limited Secures BSE Approval for Vitanosh Ingredients Merger
Lactose (India) Limited has received a no-objection observation letter from BSE Limited for its proposed merger with Vitanosh Ingredients Private Limited. The BSE issued the letter on August 22, 2025, containing no adverse observations. The merger scheme, approved by the Board of Directors in October 2024, falls under Sections 230 to 232 of the Companies Act, 2013. While this is a significant step, the merger still requires additional regulatory and statutory approvals. The company has made the BSE observation letter available on its website for transparency.
Lactose
114.
90
+
6.
60
(+
6.
09
%)
1 Year Returns:
+18.55%
Industry Peers
Sun Pharmaceutical
1,788.50
(-
0.
08
%)
Divis Laboratories
6,576.50
(+
0.
67
%)
Torrent Pharmaceuticals
4,368.50
(+
1.
17
%)
Cipla
1,375.20
(-
0.
30
%)
Zydus Life Science
1,076.60
(-
0.
16
%)
Dr Reddys Laboratories
1,263.30
(-
0.
84
%)
Lupin
2,261.20
(+
0.
51
%)
Mankind Pharma
2,369.50
(+
3.
07
%)
Aurobindo Pharma
1,440.40
(+
0.
78
%)
Laurus Labs
1,394.30
(+
0.
85
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar